• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单侧甲状腺髓样癌切除术:寻求临床实践指南。

Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines.

机构信息

Division of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Jilin Provincial Key Laboratory of Surgical Translational Medicine, Jilin Provincial Engineering Laboratory of Thyroid Disease Prevention and Control, Changchun City, China.

Division of Endocrine and Metabolic Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.

出版信息

Front Endocrinol (Lausanne). 2022 Jul 11;13:875875. doi: 10.3389/fendo.2022.875875. eCollection 2022.

DOI:10.3389/fendo.2022.875875
PMID:35898450
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9309363/
Abstract

Optimized preoperative diagnostic tools with calcitonin tests, ultrasound features, functional imaging modalities, and genetic testing to detect hereditary forms have led to an increased rate of earlier diagnosis and surgery for medullary thyroid cancer (MTC). This helps to adapt the primary surgery to the tumor stage and avoid surgical overtreatment for localized tumor growth, i.e., deviating from the regularly recommended thyroidectomy with bilateral central lymph node dissection in favor of a limited unilateral approach. To limit primary surgical therapy, it is crucial that the MTC is clinically unifocal, sporadic, and confined to the thyroid, and that calcitonin levels indicate biochemical recovery after surgery. The main requirement for such a limited approach is the availability of frozen section studies that reliably indicate (i) R0 resection of the MTC, (ii) absence of infiltration of the organ capsule, (iii) lack of desmoplasia (i.e., evidence of the metastatic potential of the MTC), (iiii) absence of contralateral disease or precancerous lesions. Informed consent is mandatory from the patient, who has been fully informed of the advantages, disadvantages, and potential risks of not undergoing the "classic" surgical procedure. The aim of this article is to review the guidelines for the management of early-stage MTC.

摘要

优化的术前诊断工具,包括降钙素检测、超声特征、功能成像方式和基因检测,用于检测遗传性形式,已导致甲状腺髓样癌(MTC)的早期诊断和手术率增加。这有助于使主要手术适应肿瘤分期,并避免对局限性肿瘤生长进行过度手术治疗,即避免常规推荐的甲状腺全切除术和双侧中央淋巴结清扫术,而倾向于采用局限性单侧手术。为了限制原发性手术治疗,MTC 在临床上必须是单灶性、散发性的,局限于甲状腺,且降钙素水平表明手术后生化恢复。这种局限性手术方法的主要要求是提供可靠指示(i)MTC 的 R0 切除,(ii)器官包膜无浸润,(iii)无纤维组织增生(即 MTC 的转移潜能的证据),(iiii)对侧无疾病或癌前病变的冷冻切片研究。患者必须知情同意,并充分了解不接受“经典”手术程序的优点、缺点和潜在风险。本文的目的是回顾早期 MTC 的管理指南。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb5/9309363/e1166fb0c3b0/fendo-13-875875-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb5/9309363/e1166fb0c3b0/fendo-13-875875-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afb5/9309363/e1166fb0c3b0/fendo-13-875875-g001.jpg

相似文献

1
Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines.单侧甲状腺髓样癌切除术:寻求临床实践指南。
Front Endocrinol (Lausanne). 2022 Jul 11;13:875875. doi: 10.3389/fendo.2022.875875. eCollection 2022.
2
[Extent of resection in intrathyroidal medullary thyroid cancer].甲状腺内髓样癌的切除范围
Chirurg. 2020 Dec;91(12):1017-1024. doi: 10.1007/s00104-020-01274-9.
3
Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci.甲状腺髓样癌的手术范围与隐匿性对侧病灶的发生率。
JAMA Otolaryngol Head Neck Surg. 2024 Mar 1;150(3):209-214. doi: 10.1001/jamaoto.2023.4376.
4
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.散发性和遗传性甲状腺髓样癌中央区及双侧淋巴结清扫的理论依据
J Clin Endocrinol Metab. 2003 May;88(5):2070-5. doi: 10.1210/jc.2002-021713.
5
[Individualization of treatment in sporadic and hereditary medullary thyroid cancer].[散发性和遗传性甲状腺髓样癌的个体化治疗]
Chirurgie (Heidelb). 2024 Mar;95(3):186-191. doi: 10.1007/s00104-023-02015-4. Epub 2024 Jan 12.
6
Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.散发性甲状腺髓样癌的手术治疗策略:我们的经验
G Chir. 2012 Nov-Dec;33(11-12):395-9.
7
Current understanding and management of medullary thyroid cancer.当前对甲状腺髓样癌的认识和管理。
Oncologist. 2013;18(10):1093-100. doi: 10.1634/theoncologist.2013-0053. Epub 2013 Sep 13.
8
Surgery for lymph node metastases of medullary thyroid carcinoma: A review.甲状腺髓样癌淋巴结转移的外科治疗:综述。
Cancer. 2016 Feb 1;122(3):358-66. doi: 10.1002/cncr.29761. Epub 2015 Nov 5.
9
A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.挪威2A型多发性内分泌腺瘤病的全国性研究:甲状腺髓样癌临床病程的预测和预后因素
Thyroid. 2016 Sep;26(9):1225-38. doi: 10.1089/thy.2015.0673. Epub 2016 Aug 11.
10
Tumor desmoplasia outperforms preoperative serum calcitonin as surgical biomarker in sporadic medullary thyroid cancer.促纤维增生性肿瘤比术前降钙素更能作为散发性甲状腺髓样癌的手术生物标志物。
Head Neck. 2024 Nov;46(11):2843-2852. doi: 10.1002/hed.27827. Epub 2024 Jun 8.

引用本文的文献

1
The value of F-FDG PET/CT and F-DOPA PET/CT in determining the initial surgical strategy of patients with medullary thyroid cancer : Preoperative PET/CT imaging for medullary thyroid cancer.F-FDG PET/CT和F-DOPA PET/CT在确定甲状腺髓样癌患者初始手术策略中的价值:甲状腺髓样癌的术前PET/CT成像
Cancer Imaging. 2025 Mar 26;25(1):41. doi: 10.1186/s40644-025-00862-4.
2
Holomics and Artificial Intelligence-Driven Precision Oncology for Medullary Thyroid Carcinoma: Addressing Challenges of a Rare and Aggressive Disease.全基因组学与人工智能驱动的甲状腺髓样癌精准肿瘤学:应对一种罕见侵袭性疾病的挑战
Cancers (Basel). 2024 Oct 13;16(20):3469. doi: 10.3390/cancers16203469.
3

本文引用的文献

1
Medullary thyroid cancer - An update.甲状腺髓样癌——最新进展
Best Pract Res Clin Endocrinol Metab. 2023 Jan;37(1):101655. doi: 10.1016/j.beem.2022.101655. Epub 2022 Mar 31.
2
Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows.降钙素原基础值与钙刺激试验在甲状腺髓样癌诊断中的应用:利与弊。
Front Endocrinol (Lausanne). 2021 Oct 13;12:754565. doi: 10.3389/fendo.2021.754565. eCollection 2021.
3
Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
分子遗传学、治疗学和 RET 抑制剂耐药性在甲状腺髓样癌中的应用及未来展望。
Cell Commun Signal. 2024 Sep 28;22(1):460. doi: 10.1186/s12964-024-01837-x.
4
Treatment and management of medullary thyroid microcarcinoma: a 10-year retrospective study from a single center.甲状腺髓样微癌的治疗和管理:单中心十年回顾性研究。
Endocrine. 2024 Dec;86(3):1081-1089. doi: 10.1007/s12020-024-03958-2. Epub 2024 Jul 15.
5
Critically evaluated key points on hereditary medullary thyroid carcinoma.对遗传性髓样甲状腺癌的关键点进行了批判性评估。
Front Endocrinol (Lausanne). 2024 Jun 11;15:1412942. doi: 10.3389/fendo.2024.1412942. eCollection 2024.
6
Measuring discrepancies between simple medullary and synchronous medullary/papillary thyroid carcinomas: a comparative cross-sectional study.测量单纯髓样甲状腺癌与同步性髓样/乳头状甲状腺癌之间的差异:一项比较性横断面研究。
Front Endocrinol (Lausanne). 2024 Jan 22;14:1301200. doi: 10.3389/fendo.2023.1301200. eCollection 2023.
7
Partial preservation of the normal thyroid gland based on tumor diameter may be possible in small medullary thyroid carcinoma: a two-center 15-year retrospective study.基于肿瘤直径,在小细胞甲状腺髓样癌中可能实现对正常甲状腺的部分保留:一项两中心15年的回顾性研究。
Front Oncol. 2023 Jul 13;13:1216394. doi: 10.3389/fonc.2023.1216394. eCollection 2023.
8
Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.降钙素阴性甲状腺髓样癌的肿瘤学结果。
Front Endocrinol (Lausanne). 2022 Nov 23;13:1025629. doi: 10.3389/fendo.2022.1025629. eCollection 2022.
家族性非髓样甲状腺癌的大型单中心系列的临床和遗传特征。
Front Endocrinol (Lausanne). 2021 Jan 7;11:589340. doi: 10.3389/fendo.2020.589340. eCollection 2020.
4
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.韩国甲状腺髓样癌患者的诊断和治疗趋势。
Endocrinol Metab (Seoul). 2020 Dec;35(4):811-819. doi: 10.3803/EnM.2020.709. Epub 2020 Nov 20.
5
Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment.降钙素基础值和激发值在甲状腺髓样癌诊断中的应用:更新的阈值和安全性评估。
J Endocrinol Invest. 2021 Mar;44(3):587-597. doi: 10.1007/s40618-020-01356-9. Epub 2020 Jul 12.
6
A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.基于增殖活性(Ki-67 和有丝分裂计数)和凝固性坏死的甲状腺髓样癌分级方案建议
Am J Surg Pathol. 2020 Oct;44(10):1419-1428. doi: 10.1097/PAS.0000000000001505.
7
Prediction of biochemical cure in patients with medullary thyroid cancer.预测甲状腺髓样癌患者的生化治愈。
Br J Surg. 2020 May;107(6):695-704. doi: 10.1002/bjs.11444. Epub 2020 Feb 28.
8
Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?甲状腺髓样癌的早期诊断:在高敏降钙素免疫测定的时代,降钙素刺激试验是否仍有指征?
Thyroid. 2020 Jul;30(7):974-984. doi: 10.1089/thy.2019.0785. Epub 2020 Apr 1.
9
Prediction of lateral neck lymph node metastasis according to preoperative calcitonin level and tumor size for medullary thyroid carcinoma.根据术前降钙素水平和肿瘤大小预测甲状腺髓样癌的颈侧淋巴结转移。
Kaohsiung J Med Sci. 2019 Dec;35(12):772-777. doi: 10.1002/kjm2.12122. Epub 2019 Sep 4.
10
Baseline and stimulated calcitonin: Thresholds for the diagnosis of medullary thyroid cancer.基线和刺激降钙素:甲状腺髓样癌诊断的阈值
Ann Endocrinol (Paris). 2019 Jun;80(3):191-192. doi: 10.1016/j.ando.2019.04.007. Epub 2019 Apr 11.